#United States #Radnor #ImmunityBio #IBRX #Anktiva

ImmunityBio, Inc. (IBRX) Class Action Lawsuit Overview

ImmunityBio, Inc., listed under NASDAQ symbol IBRX, is currently facing a class action lawsuit initiated by Kessler Topaz Meltzer & Check, LLP, aimed at protecting investor rights. For those who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, the deadline to apply for lead plaintiff status is set for May 26, 2026.

Background of the Case

The class action claims that ImmunityBio made materially false and misleading statements regarding their lead biologic product, Anktiva. Investors allege that the company misrepresented Anktiva's capabilities and potential, asserting that it was a cancer vaccine capable of curing and preventing all kinds of cancer. Such claims came under scrutiny following a warning from the FDA, which pointed out inaccuracies in statements made by Patrick Soon-Shiong, the company's Executive Chairman.

On March 24, 2026, following the FDA's announcement, ImmunityBio's stock price dropped dramatically by 21.12%, closing at $7.42 per share. Investors who felt the impact of this decline are encouraged to take action, as they may be eligible for recovery if they file for lead plaintiff status before the deadline.

Allegations Against ImmunityBio

The complaint highlights several key allegations against ImmunityBio:

1. False Claims: The company allegedly misrepresented Anktiva as a proven cancer vaccine.
2. Statements by Executives: Claims made by the Executive Chairman about Anktiva's capabilities were reportedly exaggerated, misleading investors about the product's true value.
3. Consequences of Misstatements: The class action asserts that these misrepresentations contributed to a considerable drop in stock value, adversely affecting investors.

Investors Actions and Next Steps

Affected investors have several options:

• - File for Lead Plaintiff Status: This must be completed by May 26, 2026. The lead plaintiff plays a crucial role in the legal proceedings, representing the interests of all class members and influencing the direction of the case.
• - Consult With Legal Experts: Investors are encouraged to discuss their legal rights and options with Kessler Topaz Meltzer & Check, LLP. Their consultation is free, providing a no-obligation opportunity for affected individuals to explore recovery possibilities.
• - Stay Informed: Prospective lead plaintiffs should stay updated about the developments in the case and understand the implications of their involvement in the lawsuit.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP is a well-respected law firm specializing in securities litigation. The firm has a reputation for securing significant recoveries on behalf of investors. They represent both individual and institutional investors and have been recognized for their work in this area.

Their commitment to protecting investor interests is underscored by their encouragement for affected ImmunityBio shareholders to come forward and seek justice. For more information, investors can visit KTMC's website.

In conclusion, ImmunityBio investors are urged to take swift action in light of this lawsuit. Time is of the essence, and those who may have been wronged should not miss the opportunity to assert their rights and potentially recover losses incurred during this tumultuous period.